Advertisement
Browse Subject Areas
?

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

< Back to Article

Immunization with SARS Coronavirus Vaccines Leads to Pulmonary Immunopathology on Challenge with the SARS Virus

Figure 3

Higher Dosages of SV Vaccine plus DIV and BPV Vaccine Comparisons, Experiment 2.

Serum neutralizing (neut) antibody and lung virus titers for each vaccine dosage group. A. Geometric mean serum antibody titer and standard error of the mean (S.E.) on day 56 for each vaccine dosage group. Five mice per group given 0.1 ml of vaccine intramuscularly on days 0 and 28. B. Geometric mean virus titer (log10 TCID50/g) and standard error of the mean (S.E.) in lungs on day 58 (two days after SARS-CoV challenge) for each vaccine dosage group. Seven to eight mice per group. Vaccines: double inactivated whole virus (DIV), recombinant S protein (SV), β propiolactone inactivated whole virus (BPV) with alum (+A). Analyses: A. GMT with alum greater than without alum: SV p<.001, DIV p = .014. GMT for the two BPV groups are different p = .039. Multiple regression: DIV and SV increased with alum p≤.01, no dosage effect p>.05.

Figure 3

doi: https://doi.org/10.1371/journal.pone.0035421.g003